Case histories are presented of 2 individuals (a 5-year-old girl and 64-year-old man) who developed encephalitis caused by the free-living amoeba Balamuthia mandrillaris. Both individuals survived after diagnosis and initiation of effective antimicrobial therapy. Immunostaining for Balamuthia-specific antibody levels identified the causative agent of the infections. Antimicrobial therapy with flucytosine, pentamidine, fluconazole, sulfadiazine, and a macrolide antibiotic (azithromycin or clarithromycin) was initiated. Phenothiazines (thioridazine and trifluoperazine) were also used. Both patients recovered, and there was no evidence of recrudescence of the disease at 2 and 6 years after onset of symptoms. Awareness of Balamuthia as the causative agent of encephalitis and early initiation of antimicrobial therapy were critical to the recovery of both patients. Although optimal antimicrobial therapy for Balamuthia amoebic encephalitis has yet to be determined, the antimicrobials used in these 2 cases effectively controlled the disease. These 2 individuals are the only known survivors of this otherwise fatal type of amoebic encephalitis.
Balamuthia mandrillaris is a free-living amoeba that is found in soil and is responsible for ∼100 published cases of amoebic encephalitis globally, approximately one-half of them in the United States. The disease was first recognized ∼12 years ago after a pregnant mandrill baboon died at the San Diego Wild Animal Park (San Diego) and the causative agent was isolated in culture and characterized [1, 2] . The earliest case descriptions in humans involved immunocompromised individuals, including those with HIV infection/AIDS, alcohol and drug abusers, and individuals with concurrent disease [1, [3] [4] [5] [6] [7] [8] . More recently, the bulk of cases appearing in the literature have involved children [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In addition to the above-mentioned baboon, Balamuthia enceph-alitis has been diagnosed in other primates [19, 20] , as well as in a horse [21] and a sheep [1] . The disease, which is difficult to differentiate from other types of encephalitis, has an insidious course, resulting in death in weeks to months after infection.
In soil, the amoeba may exist in a trophic (feeding) state or, more likely, as a dormant, thick-walled cyst [22] . Infection can result from soil contamination through a break in the skin or from carriage of cysts on wind-blown soil particles to the respiratory tract. In either case, the amoebas that emerge from the cysts are hematogenously transported to the CNS, where they cause a type of granulomatous encephalitis [3, 23] . Several cases have been reported of development of amoebic encephalitis from primary granulomatous facial lesions [11, 16, 18, 24] .
Most diagnoses of Balamuthia encephalitis are made after death, on the basis of detection of amoebas by indirect immunofluorescence (IIF) or conventional staining of brain tissue obtained during autopsy [1, 2] . Treatment is problematic, and the optimal antimicrobial therapy has yet to be determined. We present here 2 case histories, one of a 64-year-old man and the other of a 5-year-old girl, both California residents, who received diagnoses of Balamuthia encephalitis and who were successfully treated for this almost invariably fatal disease.
METHODS

IIF.
IIF staining was used to identify Balamuthia amoebas in brain and skin tissue obtained through biopsy. Unstained sections were deparaffinized and treated with anti-Balamuthia serum raised in a rabbit, followed by fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit serum, as described elsewhere [1, 2] . Control staining was done for Naegleria and Acanthamoeba, 2 other free-living amoebas implicated as causative agents of encephalitis.
IIF staining was also done with acute-phase (or "initial") and convalescent-phase (or "later") serum samples from both patients. Three different clinical isolates of Balamuthia (1 isolated from the above-mentioned baboon and 2 from human cases) were pooled, formalin fixed, and deposited to dry on Tefloncoated multiwell slides. Serum samples, diluted from 1:2 to 1: 4096, from the 2 patients we describe were applied to the wells, followed by washing and treatment with FITC-conjugated goat anti-human serum. Positive-and negative-control serum samples were run simultaneously. Stained preparations were examined with a fluorescence microscope.
CASE REPORTS
Case 1 (Santa Cruz County, CA).
A 64-year-old white man who had been in good health presented with progressive onset of right-side hemiparesis and speech difficulty. He had a focal seizure in the emergency department, where a CT scan revealed a low-density left parietal lobe brain lesion. MRI confirmed the presence of 2 lesions, a left parietal lesion 3 cm in diameter and a smaller, right occipital ring-enhancing lesion (figure 1A). Two weeks earlier, a biopsy had been performed on a persistent raised lesion ( cm) on the patient's right forearm. This 1.6 ϫ 1.5 lesion resulted from the patient's being pricked by a thorn from a rosebush while he was working in his backyard. The tissue revealed chronic inflammation with multinucleated giant cells, and the diagnosis was of a chronic inflammatory nodule with foreign body reaction.
The patient's medical history included ankylosing spondylitis, myocardial infarction, glaucoma, and depression. The family medical history included tuberculosis in the patient's father and brother, although the patient had always remained tuberculin negative. Extensive laboratory tests were nondiagnostic. One week after admission to the hospital, the patient underwent a biopsy of the left parietal lesion. Pathologic examination revealed an intense inflammatory vasculitis surrounding vessels and multinucleated giant cells compatible with a granulomatous vasculitis. After the brain biopsy was performed, treatment with dexamethasone was begun. The patient was discharged 10 days after admission; he was receiving treatment with prednisone (80 mg/day), in addition to dexamethasone, and cerebral vasculitis had been tentatively diagnosed.
Three days later, the patient was readmitted to the hospital. The results of fungal cultures of the initial brain biopsy specimen were negative, as were the results of acid-fast bacterial staining. A lumbar puncture was not performed. A second MRI showed multiple new enhancing lesions in the right and cerebellar hemispheres (figure 1B), and antituberculous therapy, as well as therapy with amphotericin B, doxycycline, and ceftriaxone, was initiated. Examination of brain tissue sections ( figure 2A ) and review of the original skin biopsy specimen (figure 2B) by IIF and hematoxylin-eosin staining identified the amoebas present as B. mandrillaris. Therapy with 5-fluorocytosine (flucytosine; 2 g q6h po), fluconazole (400 mg/day), pentamidine isethionate (4 mg/kg/day iv), and sulfadiazine (1.5 g q6h po) was begun. After brief use of azithromycin (500 mg/ day), a change was made to clarithromycin (500 mg/day), because CNS penetration of azithromycin is thought to be minimal. Trifluoperazine (10 mg q12h) was briefly administered Downloaded from https://academic.oup.com/cid/article-abstract/37/10/1304/450474 by guest on 10 January 2019 but was discontinued from the regimen because of increasing muscle rigidity.
The course of the patient's illness while he was in the hospital was marked by focal seizures; coma requiring ventilatory support; frequent myoclonus; renal insufficiency; elevation of hepatic enzyme levels; pancreatitis; and hyperglycemia (presumably secondary to pentamidine therapy, which was discontinued). The patient was in the intensive care unit for 7 weeks. Several MRIs showed no change in the number and size of lesions. At the time of his discharge to a rehabilitation unit (∼3 months after the initial hospitalization), the patient was dysarthric, alert, and oriented to person and place but had severely increased muscle tone, coarse tremor, and weakness. He was nonambulatory. His condition continued to improve while he remained in the rehabilitation unit. Fluconazole therapy was discontinued because of elevated levels of hepatic enzymes.
The patient was readmitted to the hospital for a third time (at approximately day 180) because of worsening mental status, increasing CNS lesions (in number and size) on MRI, and uncontrollable seizures. Fluconazole therapy was reinitiated, and the patient's condition gradually improved over the course of 11 days. This time, his hepatic enzyme levels remained normal, and he could again verbalize and was able to follow simple commands, but he remained markedly stiff and had frequent myoclonic jerking. Over the course of the next 5 years, he learned to walk independently and to perform all activities of daily living, and he was able to communicate well. MRI continued to show decreases in the size and enhancement of the numerous lesions. The patient continued to receive a regimen of fluconazole (400 mg/day) and sulfadiazine (1.5 g q6h).
Serum samples obtained during the initial phase of his illness (at approximately day 50) and at various subsequent stages were tested for Balamuthia antibody by IIF staining. The initial serum sample yielded a titer of 1:128 (at approximately day 50) for Balamuthia antibody, and later serum samples yielded titers of 1:64 (at approximately day 260), and 1:32 (after ∼5 years). The results of control staining for Naegleria and Acanthamoeba antibodies were negative. Table 1 provides a chronologic summary of the case history of this patient.
Case 2 (San Diego County, CA). A 5-year-old Hispanic girl presented with generalized seizures, fever, and MRI findings of edema in the left temporal/parietal area of the brain ( figure  3A) . She had been in good health, with normal growth and development and without hospitalizations. Her immunizations were current, and she was receiving no medications before admission. She traveled frequently to Mexico to visit relatives.
Evaluation of the patient revealed CSF pleocytosis (WBC count, 162 cells/mm 3 , with 65% neutrophils, 27% lymphocytes, and 8% monocytes; RBC count, 2 cells/mm 3 ; glucose level, 73 mg/dL; and protein level, 41 mg/dL) and abnormal electroencephalographic findings with focal changes in the left temporal lobe. Her fever persisted for several days, but seizures did not recur. She was treated presumptively with acyclovir for 21 days for herpes simplex virus (HSV) encephalitis. The results of 2 PCR assays of CSF were negative for HSV-1, as was a PCR assay for enterovirus. Also negative were the results of tests for CSF neurocysticercosis antibody, CSF Cryptococcus antigen, and serum toxoplasmosis antibody. She had elevated levels of serum IgM and IgG to Mycoplasma, and Epstein-Barr virus antibody titers consistent with past infection were found. After she completed the course of acyclovir, she was thought to be neurologically intact, and her physical condition had returned to baseline.
Despite the benign clinical course of this patient's illness, follow-up MRI performed 19 days after initial presentation demonstrated that she now had 2 large (3.0 and 3.5 cm in diameter), distinct ring-enhancing lesions surrounded by edema in the left temporal and parietal lobes, one of which is shown in figure 3B [25] . This prompted a CT-guided biopsy; examination of a biopsy specimen revealed acute suppurative and necrotizing inflammation and structures consistent with amoebas. A second opinion on the patient's condition was then sought in Mexicali, Mexico, and a partial excisional biopsy of one of the lesions was performed. Samples from this biopsy were submitted to the Centers for Disease Control and Prevention (Atlanta), and the amoebas were identified as B. mandrillaris by IIF staining (figure 2C). The patient was treated in Mexico with ketoconazole and metronidazole.
On returning to the United States for care, the patient was reevaluated for amoebic brain abscess. Clinically, she continued to do well and was without fever and headache. The only neurologic finding was mild dysphasia. The ketoconazole and metronidazole regimen was discontinued, and therapy with clarithromycin (14 mg/kg/day) and flucytosine (∼110 mg/kg/day) was initiated. After ∼2 weeks, this treatment regimen was changed to one containing azithromycin (14 mg/kg/day), flucytosine (110 mg/kg/day), fluconazole (14 mg/kg/day), thioridazine (1 mg/kg/day), and pentamidine (1 mg/kg/day).
The patient tolerated pentamidine therapy for ∼2 weeks, and then it was stopped because her creatinine level was increasing. Pentamidine therapy was started again (at approximately day 140) but was permanently discontinued after ∼1 week because of increases in the patient's serum glucose level. Azithromycin was changed to clarithromycin (14 mg/kg/day) because of persistent elevation of creatinine levels and concern about interstitial nephritis caused by azithromycin. Clinically, the patient's condition remained stable throughout this period, and she had minimal CNS symptoms (occasional headache and slight dysphasia). The patient required insulin therapy for 9 months to treat pentamidine-induced hyperglycemia. This eventually resolved, and she was maintained on the same 4-drug regimen (clarithromycin, fluconazole, flucytosine, and thioridazine) until approximately day 520. Thioridazine therapy was discontinued but was restarted when the patient had a brief generalized seizure and because of concern about reactivation of Balamuthia infection. Evaluation showed no change in her lesions, and she had no abnormal neurologic signs. Thioridazine therapy was continued until approximately day 680 (approximately year 1.9), at which time it was permanently discontinued. The patient continued receiving clarithromycin and fluconazole. Serial MRI and CT scans showed gradual resolution of the surrounding edema but persistence of 2 ring-enhancing lesions (which decreased in size from 3.5 and 3.0 cm in diameter to 2.4 and 2.7 cm, respectively), which partially calcified. The patient had no gross neurologic sequelae but experienced moderate performance problems in school.
Immunostaining of a serum sample obtained from the patient ∼7 months after her initial visit yielded a Balamuthia antibody titer of 1:64-1:128. Approximately 2 months later, the titer was 1:64, as it was again ∼2 months later. The results of control immunostaining were negative (titers of 1:2 and 1:4). Table 2 provides a chronologic summary of this patient's case history.
DISCUSSION
Because of the difficulty in diagnosing Balamuthia amoebic encephalitis and the resultant delay in initiating antimicrobial therapy, whether patients with this disease will survive is uncertain. What makes the 2 cases described in this report particularly noteworthy is (1) that diagnosis was made before death and (2) that antimicrobial therapy was initiated early enough to halt the course of disease, leading to survival of the 2 individuals.
Both patients underwent brain biopsies because of the nature of the lesions and the difficulty in making a diagnosis on the basis of the results of routine serologic and CSF testing. Brain tissue sections stained by immunofluorescence demonstrated Balamuthia amoebas in tissue. Other free-living amoebas have been implicated in amoebic encephalitis, including Naegleria fowleri and Acanthamoeba species [3, 22, 23] . Naegleria infections are of a fulminant type and are most often associated with swimming or other water activities, and Acanthamoeba infections typically occur in immunosuppressed or immunocompromised persons, which was not true of either of the 2 cases presented in this report. Methods for diagnosis of Balamuthia encephalitis include microscopic examination of hematoxylin-eosin-stained biopsy specimens, detection of amoebas in sectioned tissue by IIF, and detection of serum antibodies using IIF. Because Balamuthia encephalitis is chronic rather than fulminant, there is ample time for a build-up of antibodies that can be detected by IIF. When fresh (unfixed) brain tissue obtained through biopsy that contains lesions is available, it is possible to isolate amoebas in tissue cultures used as feeder layers, but the process is slowoften requiring days or weeks-and not realistically usable as a diagnostic aid [1, 22, 26] . The absence of specific symptoms and the difficulty in recognizing Balamuthia amoebas generally results in diagnoses being made after death. CT and MRI have been helpful in determining the size, location, and dynamics of amoebic brain lesions and have been used in ∼12 of the cases published in the literature. Given the numbers of immune-impaired individuals globally, it is likely that the disease is underreported.
The differential diagnosis for Balamuthia encephalitis includes mycobacterial tuberculosis [6, 7, 10, 12, 14, 27] and neurocysticercosis [12, 27, 28] . In one case described in the literature, in which neurocysticercosis was initially diagnosed, histologic study after autopsy led to reporting of the case as Acanthamoeba encephalitis [29] , and the case was subsequently identified by immunostaining to be Balamuthia encephalitis (G.S.V., unpublished observations). The patient in case 1 in this report was initially treated for tuberculosis before amoebas were identified in brain tissue, and cysticercosis was considered as a possibility in case 2. Until MRI findings became available, at approximately day 60, the patient in case 2 was treated as if she had HSV encephalitis, despite negative results of 2 HSV PCR assays. Balamuthia encephalitis should be considered as a possible diagnosis for patients being treated for presumptive HSV encephalitis when the diagnosis of HSV infection is not supported by PCR or other test results. It should also be considered for patients with cutaneous lesions and nonspecific granulomatous pathology in the absence of microbial involvement [16] , as was true for the patient in case 1.
The optimal antimicrobial therapy for Balamuthia infection has yet to be determined. The selection of antimicrobials used to treat these 2 patients was based on unpublished and published in vitro studies of drug efficacy against clinical isolates of Balamuthia. In both cases, the core of antimicrobials administered included pentamidine, flucytosine, fluconazole, a macrolide antibiotic (azithromycin or clarithromycin), and sulfadiazine. Amphotericin B, which is effective against Naegleria species [30] , varies in its efficacy against Balamuthia isolates [31] . Amphotericin B was used unsuccessfully in treating 2 other patients with Balamuthia encephalitis, along with trimethoprim-sulfamethoxazole [13] and fluconazole [32] . In vitro testing of pentamidine isethionate indicated that it was effective against clinical isolates of Balamuthia [31, 33] . A study of pentamidine distribution in patients with HIV infection/ AIDS reported slow uptake (∼30 days) into the CNS [34] . Therapy with pentamidine, which was administered over the course of ∼25 days in both of the cases we describe (tables 1 and 2), was discontinued because of hyperglycemia that developed and that, for the patient in case 1, has persisted. Phenothiazine compounds have shown in vitro efficacy against Balamuthia, although these tend to be toxic to tissue culture cells at concentrations that are amoebicidal [33] . Thioridazine was used in case 2, and trifluoperazine was used in case 1, but it is difficult to assess the efficacy of these drugs, among the other antimicrobial agents used, in the patients' recovery. In neither of the 2 cases were amoebas isolated from the patients' biopsied brain tissue, and thus the antimicrobial sensitivity of the infecting amoebas is unresolved.
The source of the infection in case 1 would appear to have been the wound that the patient received while working in his garden. Given the circumstances, it is likely that the wound was contaminated with soil, offering a portal of entry for the amoeba. No focal source of infection was evident in case 2.
The recovery of these 2 patients after timely diagnosis and treatment indicates that Balamuthia amoebic encephalitis cases need not invariably be fatal. With greater awareness that this amoeba can be a causative agent of encephalitis, earlier diagnosis can be made either by immunostaining or by recognizing the amoebas in histologic sections of brain tissue after biopsy. At present, the Centers for Disease Control and Prevention and the California State Department of Health Services are able to perform IIF testing of serum samples and tissue sections as an aid to diagnosis. Premortem diagnosis, coupled with effective antimicrobial therapy, may significantly reduce the mortality associated with this type of encephalitis.
